|
|
||||||||
CUTTING EDGE |
and p110
, in Lymphocyte Chemotaxis and Homing1



* Howard Hughes Medical Institute and Department of Microbiology and Immunology, University of California, San Francisco, CA 94143;
Molecular Immunology Programme, The Babraham Institute, Cambridge, United Kingdom;
The 21st Century Center of Excellence Program, Akita University School of Medicine and Precursory Research for Embryonic Science and Technology, Hondo, Akita, Japan;
Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria; and
¶
Cell Signalling Group, Ludwig Institute for Cancer Research, and Department of Biochemistry and Molecular Biology, University College, London, United Kingdom.
| Abstract |
|---|
|
|
|---|
-deficient T cells, but not B cells, show reduced chemotactic responses to the lymphoid chemokines, CCL19, CCL21, and CXCL12. As B cell and T cell chemotactic responses were both sensitive to the general PI3K inhibitors, wortmannin (WMN) and LY294002, we explored whether B cell responses were affected in mice lacking p110
, a major PI3K isoform in lymphocytes. B cells deficient in p110
showed diminished chemotactic responses, especially to CXCL13. Adoptive transfer experiments with WMN-treated wild-type B cells and with p110
-deficient B cells revealed diminished homing to Peyers patches and splenic white pulp cords. WMN selectively inhibited CXCR5-dependent B cell homing to Peyers patches. These observations establish that p110
and p110
function in lymphocyte chemotaxis, and show differential roles for PI3K family members in B and T cell migration. | Introduction |
|---|
|
|
|---|
Efforts to dissect the mechanisms of eukaryotic cell chemotaxis toward attractants acting via G protein-coupled receptors, principally performed in neutrophils and in the slime mold Dictyostelium discoideum, have established an important role for PI3Ks (3, 4). PI3Ks function to relay the chemoattractant gradient to the inside of the cell, generating high concentrations of phosphatidylinositol 3,4,5-trisphosphate at the leading edge (3, 4). Consistent with this, neutrophils and macrophages from mice lacking p110
, a class IB PI3K that couples to heterotrimeric G proteins, are poorly responsive to chemoattractants (reviewed in Refs. 5 , 6). By contrast, lymphocyte migration was not reported to be affected in these animals. However, studies with pharmacological inhibitors of PI3K, wortmannin (WMN)4 and LY294002, and with dominant-negative forms of PI3K have provided evidence that PI3K contributes to lymphocyte chemotactic responses (2).
In this study, we examined the PI3K requirement for naive lymphocyte responses to lymphoid chemokines. We show that p110
functions in T cell chemotaxis and that a class IA PI3K, p110
, is required for maximal B cell chemotaxis to CXCL13 and for B cell homing to Peyers patches (PPs) and to the splenic white pulp.
| Materials and Methods |
|---|
|
|
|---|
CXCR5/ mice and IgHEL-transgenic mice of the MD4 line were on a C57BL/6 (B6) background (7). IghaThy1aGpi1a B6 mice (termed Igha) were from The Jackson Laboratory (Bar Harbor, ME). B6 or B6-CD45.1 (Ly5.2) mice were from Charles River Laboratories (Wilmington, MA) or a University of California colony (San Francisco, CA). The mice deficient in p110
(8) and p110
(9) were three or six generations backcrossed to B6, respectively. To provide p110
/ or p110
D910A/D910A cells for homing and migration assays, lethally irradiated B6-Ly5.2 mice were reconstituted as described (10) with p110
/, p110
D910A/D910A, or littermate control (+/+ or +/) bone marrow.
Adoptive transfer assays
Donor splenocytes were prepared at 106/ml (10). For WMN experiments followed by histological examinations, B6 or IgHEL-transgenic splenocytes were labeled for 10 min at 37°C with 1.4 µM or 0.14 µM CFSE (Molecular Probes, Eugene, OR), cotreated with either 200 nM WMN (Sigma-Aldrich, St. Louis, MO) or carrier, and washed three times in RPMI 1640 plus 10% FBS. Carrier- and WMN-treated cells were transferred alone (3 x 107) or after mixing (4 x 107), and injected i.v. into Igha B6 recipients. Spleens were harvested and analyzed as described (10). For WMN treatment experiments followed by flow cytometry, CXCR5/ or wild-type splenocytes were treated for 30 min at 37°C with 200 nM WMN or carrier, and labeled at the same time with either 1 µM CFSE or 10 µM CellTracker Orange 5- (and 6-)-(((4-chloromethyl)benzoyl)amino)tetramethylrhodamine (CMTMR) (Molecular Probes), washed, and mixed at a 1:1 ratio, and 3 x 107 cells were transferred. Splenocytes from p110
D910A/D910A, p110
/, or littermate control chimeras labeled with 1.4 µM CFSE and from IgHEL-transgenic mice labeled with 0.14 µM CFSE were mixed at a 3:1 ratio and 4 x 107 total cells were transferred as above. The absolute frequency of p110 knockout or wild-type B cells to cotransferred control B cells in any given tissue was determined by dividing the absolute number of recovered cells by the absolute number of cotransferred IgHEL control cells. Blood sample numbers are based on a total volume of 2 ml of blood per mouse. The frequency was corrected for differences in the input ratio of p110 knockout or wild-type cells and IgHEL control cells, and transfer data were plotted as the number of cells of each type recovered in each recipient per 106 transferred cells as described (11). The absolute number of WMN-treated vs carrier-treated CXCR5/ or CXCR5+/+ B cells were determined as for the p110 transfer experiments, except that numbers were not normalized to a cotransferred control cell population because carrier- or WMN-treated cells were cotransferred into the same recipient mouse. All statistical analyses were conducted using a two-tailed, two sample, unequal variance (unpaired) Students t test.
Chemotaxis, flow cytometry, and immunohistochemistry
Chemotaxis assays were with splenocytes as described (10) using uncoated 5-µm transwell filters (Corning Costar, Acton, MA) and chemokines from R&D Systems (Minneapolis, MN). In some experiments, cells were pretreated for 10 min with the indicated concentrations of WMN, with 5 µM LY294002 (Calbiochem, San Diego, CA) or carrier before the assay. Flow cytometry for chemokine receptors and immunohistochemical analysis was as described (10, 12). Cell enumeration was performed by locating well-defined mucosal addressin cell adhesion molecule-1-stained (BD Pharmingen, San Diego, CA) white pulp cords from serial sections costained with either IgMb and IgDb or hen egg lysozyme (HEL) to detect transferred B6 B cells or IgHEL-transgenic (transgenic for IgM and IgD with Igha) B cells, respectively. Cotransferred B cells were enumerated within three serial white pulp cord sections per mouse.
| Results and Discussion |
|---|
|
|
|---|
To examine the PI3K dependence of naive lymphocyte responses to lymphoid chemokines, spleen cells were incubated with 100 nM WMN and subjected to transwell chemotaxis assays. B cell responses to each of the lymphoid chemokines were inhibited between 65 and 85% by WMN treatment, with the inhibitory effect being most prominent at the lower chemokine doses (Fig. 1). By contrast, T cell responses were more resistant to the inhibitor, especially the responses to the efficacious T cell attractant, CCL21, where the maximal inhibitory effect was 3565% for CD4 cells (Fig. 1). Increasing the WMN concentration to 250 nM led to only a slight increase in inhibition, and there was no further increase when 500 or 1000 nM concentrations were used (data not shown). Similar findings were obtained using a second PI3K inhibitor, LY294002 (data not shown). As expected from its covalent mechanism of action, WMN inhibitory effects were still evident at
75% of the initial level 6 h after the inhibitor had been removed from the cultures (data not shown). These findings extend previous studies showing that lymphocyte responses to CCL5 (RANTES) and CXCL12 can be reduced or inhibited by WMN treatment (reviewed in Ref. 2), and they indicate that different lymphoid chemokine receptors have differing dependence on PI3K for mediating chemotactic responses. The basis for the incomplete block in migration is unclear, but may indicate the involvement of PI3K-independent pathways of chemotaxis in lymphocytes (1, 2, 4).
|
in T cell migration and p110
in B cell migration
Although previous studies of p110
-deficient mice had not indicated a role for this PI3K isoform in lymphocyte migration, our findings above led us to test whether p110
-deficient lymphocytes showed partial defects in chemotactic responsiveness. Flow cytometric analysis revealed that chemokine receptor levels on p110
-deficient B and T cells were equivalent to wild-type controls (data not shown). However, the migration of p110
-deficient CD4 and CD8 T cells to CCL19 and CXCL12, and to low doses of CCL21, was reduced by 3065% (Fig. 2B). By contrast, B cell migration to chemokines was not significantly affected by p110
deficiency (Fig. 2B).
|
, a major PI3K isoform in lymphocytes (5, 6), was involved in B cell chemotaxis. PI3K p110
-deficient B cells had normal amounts of CCR7 and CXCR5 but exhibited slightly elevated CXCR4 levels (Fig. 2A). Elevated CXCR4 levels were also seen in B cells following WMN treatment (data not shown). CCR7 and CXCR4 levels on p110
-deficient T cells were equivalent to the wild-type controls. Strikingly, p110
-deficient B cells showed a defect in B cell chemotaxis to all concentrations of CXCL13 (Fig. 2C). Responses to the CCR7 and CXCR4 ligands were less affected, but slight reductions in migration were detected at the lower CCL19 and CXCL12 concentrations (Fig. 2C). T cell responses were unaffected by p110
deficiency, with the exception that responses to low doses of CXCL12 were reduced (Fig. 2C).
The ability of p110
to function downstream of chemokine receptors in lymphocyte chemotactic responses is consistent with the finding that dominant-negative p85 reduces chemotaxis to CXCL12 (13, 14). Recently, a small molecule inhibitor of p110
was identified and shown to reduce neutrophil chemotaxis to fMLP in under agarose assays, with ICAM1 as an adhesive substrate (15). The mechanism of p110
coupling to chemokine receptors is unclear, but because tyrosine kinases can be activated by chemoattractant receptors, the conventional pathway of class IA PI3K activation may be involved (4). Consistent with this scenario, microinjection of p110
neutralizing Abs inhibited tyrosine-kinase receptor-mediated migratory responses of a macrophage cell line to CSF-1 (16).
Requirement of p110
for B cell homing
To explore the role of PI3K in B cell homing in vivo, we transferred wild-type B cells that had been treated in vitro with WMN, or cells from p110
- or p110
-deficient mice, into wild-type recipients for 1.5 h. These experiments revealed reduced homing to PP of both WMN-treated and p110
-deficient B cells, but normal homing of p110
-deficient B cells (Fig. 3A). p110
deficiency also caused a reduction in homing to mesenteric lymph node (LN), although this effect was weaker than the effect in PP and it was not evident with WMN-treated cells. Entry into peripheral LN and to the spleen was not reduced by WMN treatment or by p110
or p110
deficiency (Fig. 3A). Analysis of lymphoid organs in p110
-deficient mice revealed that B cell numbers were severely diminished in PP (1.55 ± 1.2 x 106, n = 4, in wild-type vs 0.07 ± 0.01 x 106, n = 5, in p110
-deficient) whereas numbers in LNs and spleen were not significantly reduced. This finding is consistent with p110
playing a nonredundant role in B cell accumulation in PP.
|
deficiency strongly affected CXCL13 responses in vitro, and other studies have shown that entry to PP but not peripheral LN depends partially on CXCR5 (11), we tested whether the PI3K requirement for B cell entry to PP was due to PI3K acting downstream of CXCR5. For these experiments, cells from wild-type or CXCR5-deficient mice were treated with WMN or with the carrier, and then transferred to wild-type recipients. Analysis 1.5 h later revealed that homing of CXCR5-deficient B cells to PP was reduced
65% (Fig. 3B) as expected (11). However, WMN treatment did not cause a further reduction in the PP homing of the CXCR5-deficient cells, in contrast to its inhibitory effect on the homing of wild-type cells (Fig. 3B). Therefore, we conclude that p110
has a selective role in B cell entry to PP via CXCL13+ high endothelial venules (HEV). Although WMN treatment was not found to affect lymphocyte attachment to PP HEV in a previous study (17), it was not indicated whether T or B lymphocytes were being analyzed and it seems possible that the HEV under investigation were the larger CXCL13-negative vessels present in the T zone. Alternatively, the role of p110
may be restricted to a CXCL13-dependent step downstream of attachment but required for B cell accumulation within the organ.
When the distribution of WMN-treated B cells within the spleen was examined 1.5 h after transfer, a strong reduction was observed in B cell entry to splenic white pulp cords (Fig. 4, A (upper panels) and B). Reduced white pulp entry was also observed for p110
-deficient cells, whereas p110
deficiency had no effect on entry (Fig. 4B). B cell entry into the splenic white pulp cords depends on CXCR5, and to a lesser degree on CCR7 (18) and on the integrins
L
2 and
4
1 (12). Therefore, the PI3K requirement during B cell entry to white pulp cords may reflect the role of p110
in CXCR5-mediated chemotaxis or possibly a role in CXCR5-mediated integrin activation.
|
In summary, we establish differential roles for p110
and p110
in T and B cell chemotaxis, demonstrating a particularly prominent role for p110
in B cell responses to CXCL13. Differential PI3K usage by different chemokine receptors and different cell types is likely to be important in allowing cells to appropriately interpret complex chemokine environments, such as those that exist within lymphoid organs.
| Acknowledgments |
|---|
| Footnotes |
|---|
1 This work was supported by the Leukemia and Lymphoma Society (to K.R.), the Howard Hughes Medical Institute (to J.G.C.), and National Institutes of Health Grant AI-40098 (to J.G.C.). Research in the laboratory of B.V. is funded by the Ludwig Institute for Cancer Research, the Biotechnology and Biological Science Research Council, and the European Union Fifth Framework Programme QLG1-2001-02171. ![]()
2 Current address: Department of Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. ![]()
3 Address correspondence and reprint requests to Dr. Jason G. Cyster, Department of Microbiology and Immunology, University of California, 513 Parnassus Ave., San Francisco, CA 94143. E-mail address: cyster{at}itsa.ucsf.edu ![]()
4 Abbreviations used in this paper: WMN, wortmannin; LN, lymph node; PP, Peyers patch; HEL, hen egg lysozyme; HEV, high endothelial venule; CMTMR, 5- (and 6-)-(((4-chloromethyl)benzoyl)amino)tetramethylrhodamine. ![]()
Received for publication April 20, 2004. Accepted for publication June 18, 2004.
| References |
|---|
|
|
|---|
and its lipid products. Trends Cell Biol. 10:466.[Medline]
in thymocyte development, T cell activation, and neutrophil migration. Science 287:1040.
PI 3-kinase mutant mice. Science 297:1031.
-induced lymphocyte polarization and chemotaxis. J. Immunol. 163:4001.
in neutrophil directional movement. J. Immunol. 170:2647.
2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity 13:759.[Medline]
This article has been cited by other articles:
![]() |
K. Gollmer, F. Asperti-Boursin, Y. Tanaka, K. Okkenhaug, B. Vanhaesebroeck, J. R. Peterson, Y. Fukui, E. Donnadieu, and J. V. Stein CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway Blood, July 16, 2009; 114(3): 580 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Saudemont, F. Garcon, H. Yadi, M. Roche-Molina, N. Kim, A. Segonds-Pichon, A. Martin-Fontecha, K. Okkenhaug, and F. Colucci p110{gamma} and p110{delta} isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease PNAS, April 7, 2009; 106(14): 5795 - 5800. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Matsuda, Y. Mikami, M. Ohtani, M. Fujiwara, Y. Hirata, A. Minowa, Y. Terauchi, T. Kadowaki, and S. Koyasu Critical role of class IA PI3K for c-Rel expression in B lymphocytes Blood, January 29, 2009; 113(5): 1037 - 1044. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Webb, A. Johnson, M. Fortunato, A. Platt, T. Crabbe, M. I. Christie, G. F. Watt, S. G. Ward, and L. A. Jopling Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists J. Leukoc. Biol., October 1, 2008; 84(4): 1202 - 1212. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Thomas, J. S. Mitchell, C. C. DeNucci, A. L. Martin, and Y. Shimizu The p110{gamma} isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites J. Leukoc. Biol., September 1, 2008; 84(3): 814 - 823. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. J. de Gorter, R. M. Reijmers, E. A. Beuling, H. P. H. Naber, A. Kuil, M. J. Kersten, S. T. Pals, and M. Spaargaren The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells Blood, April 1, 2008; 111(7): 3364 - 3372. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fougerat, S. Gayral, P. Gourdy, A. Schambourg, T. Ruckle, M. K. Schwarz, C. Rommel, E. Hirsch, J.-F. Arnal, J.-P. Salles, et al. Genetic and Pharmacological Targeting of Phosphoinositide 3-Kinase-{gamma} Reduces Atherosclerosis and Favors Plaque Stability by Modulating Inflammatory Processes Circulation, March 11, 2008; 117(10): 1310 - 1317. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Martin, M. D. Schwartz, S. C. Jameson, and Y. Shimizu Selective Regulation of CD8 Effector T Cell Migration by the p110{gamma} Isoform of Phosphatidylinositol 3-Kinase J. Immunol., February 15, 2008; 180(4): 2081 - 2088. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Heit, L. Liu, P. Colarusso, K. D. Puri, and P. Kubes PI3K accelerates, but is not required for, neutrophil chemotaxis to fMLP J. Cell Sci., January 15, 2008; 121(2): 205 - 214. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Janas, D. Hodson, Z. Stamataki, S. Hill, K. Welch, L. Gambardella, L. C. Trotman, P. P. Pandolfi, E. Vigorito, and M. Turner The Effect of Deleting p110{delta} on the Phenotype and Function of PTEN-Deficient B Cells J. Immunol., January 15, 2008; 180(2): 739 - 746. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nakhaei-Nejad, A. M. Hussain, Q.-X. Zhang, and A. G. Murray Endothelial PI 3-kinase activity regulates lymphocyte diapedesis Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3608 - H3616. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Haynes, C. D. C. Allen, R. Lesley, K. M. Ansel, N. Killeen, and J. G. Cyster Role of CXCR5 and CCR7 in Follicular Th Cell Positioning and Appearance of a Programmed Cell Death Gene-1High Germinal Center-Associated Subpopulation J. Immunol., October 15, 2007; 179(8): 5099 - 5108. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ji, F. Rintelen, C. Waltzinger, D. Bertschy Meier, A. Bilancio, W. Pearce, E. Hirsch, M. P. Wymann, T. Ruckle, M. Camps, et al. Inactivation of PI3K{gamma} and PI3K{delta} distorts T-cell development and causes multiple organ inflammation Blood, October 15, 2007; 110(8): 2940 - 2947. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Bach, Q.-M. Chen, W. T. Kerr, Y. Wang, L. Lian, J. K. Choi, D. Wu, M. G. Kazanietz, G. A. Koretzky, S. Zigmond, et al. Phospholipase Cbeta Is Critical for T Cell Chemotaxis J. Immunol., August 15, 2007; 179(4): 2223 - 2227. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Matheu, J. A. Deane, I. Parker, D. A. Fruman, and M. D. Cahalan Class IA Phosphoinositide 3-Kinase Modulates Basal Lymphocyte Motility in the Lymph Node J. Immunol., August 15, 2007; 179(4): 2261 - 2269. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Asperti-Boursin, E. Real, G. Bismuth, A. Trautmann, and E. Donnadieu CCR7 ligands control basal T cell motility within lymph node slices in a phosphoinositide 3-kinase- independent manner J. Exp. Med., May 14, 2007; 204(5): 1167 - 1179. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Nombela-Arrieta, T. R. Mempel, S. F. Soriano, I. Mazo, M. P. Wymann, E. Hirsch, C. Martinez-A., Y. Fukui, U. H. von Andrian, and J. V. Stein A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated egress J. Exp. Med., March 19, 2007; 204(3): 497 - 510. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Brauweiler, K. Merrell, S. B. Gauld, and J. C. Cambier Cutting Edge: Acute and Chronic Exposure of Immature B Cells to Antigen Leads to Impaired Homing and SHIP1-Dependent Reduction in Stromal Cell-Derived Factor-1 Responsiveness J. Immunol., March 15, 2007; 178(6): 3353 - 3357. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-J. Liao, M.-C. Huang, M. Graler, Y. Huang, H. Qiu, and E. J. Goetzl Distinctive T Cell-suppressive Signals from Nuclearized Type 1 Sphingosine 1-Phosphate G Protein-coupled Receptors J. Biol. Chem., January 19, 2007; 282(3): 1964 - 1972. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Okkenhaug, D. T. Patton, A. Bilancio, F. Garcon, W. C. Rowan, and B. Vanhaesebroeck The p110{delta} Isoform of Phosphoinositide 3-Kinase Controls Clonal Expansion and Differentiation of Th Cells J. Immunol., October 15, 2006; 177(8): 5122 - 5128. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. B. Hickey and T. G. Cotter BCR-ABL Regulates Phosphatidylinositol 3-Kinase-p110{gamma} Transcription and Activation and Is Required for Proliferation and Drug Resistance J. Biol. Chem., February 3, 2006; 281(5): 2441 - 2450. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Yopp, J. C. Ochando, M. Mao, L. Ledgerwood, Y. Ding, and J. S. Bromberg Sphingosine 1-Phosphate Receptors Regulate Chemokine-Driven Transendothelial Migration of Lymph Node but Not Splenic T Cells J. Immunol., September 1, 2005; 175(5): 2913 - 2924. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Badr, G. Borhis, D. Treton, and Y. Richard IFN{alpha} enhances human B-cell chemotaxis by modulating ligand-induced chemokine receptor signaling and internalization Int. Immunol., April 1, 2005; 17(4): 459 - 467. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |